The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil

The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil

Bibliographic Details
Main Authors:	Flávia Rossi, Ana P. Cury, Maria R.G. Franco, Raymond Testa, Wright W. Nichols
Format:	Article
Language:	English
Published:	Elsevier 2017-09-01
Series:	Brazilian Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867016306390

Similar Items

Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection
by: Shuang Xiao, et al.
Published: (2023-08-01)

Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection
by: Zihao Zheng, et al.
Published: (2023-10-01)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
by: Paolo Gaibani, et al.
Published: (2022-05-01)

In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014–2018
by: Elkin V. Lemos-Luengas, MD, PhD, et al.
Published: (2022-06-01)

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
by: Tingting Xu, et al.
Published: (2022-04-01)

In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015–2021
by: Luis C. Torres-Castillo, et al.
Published: (2023-12-01)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021-09-01)

Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria
by: Kozlov R.S., et al.
Published: (2018-02-01)

Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
by: Thaisa Noceti Carvalho, et al.
Published: (2023-01-01)

Resistance to ceftazidime–avibactam and underlying mechanisms
by: Yuhang Wang, et al.
Published: (2020-09-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
by: Marie Kempf, et al.
Published: (2022-12-01)

Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022-04-01)

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study
by: Reena Rajan, et al.
Published: (2024-01-01)

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU
by: Yu J, et al.
Published: (2023-09-01)

Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam
by: Huan Kuang, et al.
Published: (2020-12-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
by: Lin Wang, et al.
Published: (2022-06-01)

Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024-01-01)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
by: Qiaozhen Cui, et al.
Published: (2023-11-01)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
by: Xiaoyan Cui, et al.
Published: (2020-06-01)

In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018
by: Elkin V. Lemos-Luengas, et al.
Published: (2022-05-01)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01)

34: SYSTEMATIC IN VITRO INTERACTION STUDY ON CEFTAZIDIME/AVIBACTAM AND FOSFOMYCIN
by: Niklas Kroemer, et al.
Published: (2022-11-01)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023-12-01)

In Vitro Activity of Aztreonam-avibactam and Ceftazidime-avibactam against Pseudomonas aeruginosa Collected in a Global Surveillance Program in the Africa/Middle East, 2014–2017
by: I Morrissey, et al.
Published: (2020-02-01)

PB2285: CLINICAL EXPERIENCE WITH CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF BACTEREMIA DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA IN HEMATOLOGIC PATIENTS
by: S. Zhen, et al.
Published: (2022-06-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria
by: Michaela Simon, et al.
Published: (2022-11-01)

Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review
by: Zhou Q, et al.
Published: (2021-05-01)

In vitro activity of ceftazidime–avibactam and comparators against Gram-negative bacterial isolates collected in the Asia–Pacific region as part of the INFORM program (2015–2017)
by: Wen-Chien Ko, et al.
Published: (2020-04-01)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
by: Marco Fiore, et al.
Published: (2020-07-01)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
by: Kalyani Borde, et al.
Published: (2023-10-01)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
by: Wei Yu, et al.
Published: (2021-11-01)

In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
by: Michael Kresken, et al.
Published: (2021-06-01)

Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria
by: Xueyun Zhu, et al.
Published: (2024-03-01)

In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales
by: Papa-Ezdra Romina, et al.
Published: (2023-12-01)

Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
by: Natália Kehl Moreira, et al.
Published: (2023-11-01)

74: TREATING CARBAPENEMASE-PRODUCING ENTEROBACTERALES UROSEPSIS WITH CEFTAZIDIME/AVIBACTAM IN PREGNANCY
by: C. Kendrick, et al.
Published: (2022-11-01)